Cargando…

COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking

SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes ther...

Descripción completa

Detalles Bibliográficos
Autor principal:	Magro, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305708/ https://www.ncbi.nlm.nih.gov/pubmed/32569708 http://dx.doi.org/10.1016/j.virusres.2020.198070

Ejemplares similares

Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2
por: Niranjan, Vidya, et al.
Publicado: (2022)

Correction to: Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2
por: Niranjan, Vidya, et al.
Publicado: (2022)

SARS-CoV-2 and cancer: the intriguing and informative cross-talk
por: Goubran, Hadi, et al.
Publicado: (2022)

Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2
por: Al-Karmalawy, Ahmed A., et al.
Publicado: (2021)

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
por: Díez, José María, et al.
Publicado: (2020)

SARS-CoV-2 and coagulation disorders in different organs
por: Vinayagam, Sathishkumar, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
por: Magro, Giuseppe
Publicado: (2020)

While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?
por: Barrantes, Francisco J.
Publicado: (2020)

Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review
por: Sakr, Masarra M., et al.
Publicado: (2021)

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs
por: Chan, Wallace K. B., et al.
Publicado: (2022)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2
por: Pavoni, Vittorio, et al.
Publicado: (2020)

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2
por: Yin, Shiyu, et al.
Publicado: (2020)

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
por: Bates, Timothy A., et al.
Publicado: (2020)

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
por: Bates, Timothy A., et al.
Publicado: (2021)

Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2
por: Grahl, Matheus V.C., et al.
Publicado: (2021)

Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
por: Jung, Christoph, et al.
Publicado: (2022)

Regulatory Cross Talk Between SARS-CoV-2 Receptor Binding and Replication Machinery in the Human Host
por: Ahmed, Shiek S. S. J., et al.
Publicado: (2020)

Possible kidney-lung cross-talk in COVID-19: in silico modeling of SARS-CoV-2 infection
por: Grigoryev, Dmitry N., et al.
Publicado: (2022)

Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor
por: Eslamifar, Zahra, et al.
Publicado: (2020)

Gene variants of coagulation related proteins that interact with SARS-CoV-2
por: Holcomb, David, et al.
Publicado: (2021)

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
por: Xue, Yiying, et al.
Publicado: (2023)

Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017
por: Jia, Yunfei, et al.
Publicado: (2022)

Drug Weaponry to Fight Against SARS-CoV-2
por: Cabezón, Elena, et al.
Publicado: (2020)

Phytochemicals against SARS-CoV as potential drug leads
por: Swain, Shasank Sekhar, et al.
Publicado: (2021)

MERS-CoV: Understanding the Latest Human Coronavirus Threat
por: Chafekar, Aasiyah, et al.
Publicado: (2018)

Cross-viral protection against SARS-CoV-2?
por: Reed, Sophie G.
Publicado: (2020)

Commonly available but highly effective protection against SARS-CoV-2 during gastrointestinal endoscopies
por: Keil, Radan, et al.
Publicado: (2021)

Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach
por: Dal-Ré, Rafael, et al.
Publicado: (2022)

New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?
por: Rapti, Vasiliki, et al.
Publicado: (2022)

The Impact of SARS-CoV-2 on Inflammatory Bowel Disease
por: Estevinho, Maria Manuela, et al.
Publicado: (2020)

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Investigation of Coagulation Biomarkers to Assess Clinical Deterioration in SARS-CoV-2 Infection
por: Billoir, Paul, et al.
Publicado: (2021)

SUMO pathway, blood coagulation and oxidative stress in SARS-CoV-2 infection
por: Ibrahim, Iman Hassan, et al.
Publicado: (2021)

Laboratory diagnosis of SARS-CoV-2: available approaches and limitations
por: Abduljalil, J.M.
Publicado: (2020)

Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases
por: Chaudhry, M. Zeeshan, et al.
Publicado: (2022)

Evaluation of Novel Guanidino-Containing Isonipecotamide Inhibitors of Blood Coagulation Factors against SARS-CoV-2 Virus Infection
por: De Maio, Flavio, et al.
Publicado: (2022)

Candidate drugs against SARS-CoV-2 and COVID-19
por: McKee, Dwight L., et al.
Publicado: (2020)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lep9baac9ds6p1c542e23kn4kb